Fig. 2From: Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trialMean (± standard deviation) Functional Assessment of Cancer Therapy-Breast (FACT-B) total scores over time by diarrhea grade for a neratinib and b placebo. For FACT-B: minimally important difference, 7–8 points [16]. A higher score indicates a better quality of lifeBack to article page